Last updated: 2026-11-14 20:06:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
ProKidney Corp. (PROK) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.05, with a market capitalization of $240.32M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.87 to $2.65. This page covers its latest market performance, valuation, price trends and company information.
$240.32M | |
$1.16 | |
$1.16 | |
$1.02 | |
$1.15 | |
1.24M | |
1.43M | |
-- | |
$2.65 | |
$0.87 | |
-- | |
-- |
ProKidney Corp. (PROK) last closed at $1.05 as of 2026-11-14 00:31:00, down 9.13% ($0.10) from the previous close of $1.15.
During the latest regular trading session, PROK traded between $1.02 and $1.16, with a volume of 1.24M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, ProKidney Corp. (PROK) moved from $1.07 to $1.05, representing a decline of 1.88% ($0.02).
The stock traded between $1.00 and $1.27 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1.04 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 9.8%
PROK is currently trading at $1.05, placing it 9.8% of the way from its 52-week low of $0.87 to its 52-week high of $2.65. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 231 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to ProKidney Corp. and PROK stock.
ProKidney Corp. (PROK) reported a quarterly loss of $0.17 per share, missing consensus estimates of $0.13 by 30.77%. Revenue of $0.17 million also fell short of expectations by 13%. The stock has declined 49.6% year-to-date, significantly underperforming the S&P 500's 11.3% gain. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 41.67 percent decrease over losses of $(0.12) per share from the
Merck KGaA reported quarterly earnings of $0.24 per share, missing consensus estimates of $0.50 by 52%, though revenues of $6.48 billion exceeded expectations by 5.32%. The stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. ProKidney Corp. is also mentioned as an upcoming earnings reporter in the same Medical-Drugs industry.
Eligible investors can buy real shares of ProKidney Corp. (PROK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to PROK, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between PROK shares and USD.
PROK Shares to USD
1.00 PROK shares = 1.045 USD
Calculations are estimates based on the latest available price and are for reference only.
